Sign in
DMRA Stock Price, Chart, Stats & News
Damora Therapeutics, Inc.
Save
Damora Therapeutics, Inc. (DMRA) does not currently pay a dividend.
1.28B
Market cap
–
Current P/E
–
Forward P/E
DMRA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.01% |
ROA | -147.58% |
ROE | -147.05% |
D/E | 0.21x |
Interest coverage ratio | – |
DMRA valuation
P/E | – |
P/S | – |
P/B | 5.08x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | -0.27x |
EV multiple | -130.28x |
About
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Similar securities
Based on sector and market capitalization
Report issue